Autolus Therapeutics (NASDAQ:AUTL) and Neuralstem (NASDAQ:CUR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Profitability

This table compares Autolus Therapeutics and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Autolus Therapeutics -3,576.93% -39.54% -33.58%
Neuralstem -39,417.64% -170.51% -110.16%

Earnings and Valuation

This table compares Autolus Therapeutics and Neuralstem’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Autolus Therapeutics $1.41 million 290.45 -$12.86 million ($1.42) -7.18
Neuralstem $260,000.00 8.48 -$4.93 million N/A N/A

Neuralstem has lower revenue, but higher earnings than Autolus Therapeutics.

Volatility & Risk

Autolus Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Neuralstem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Autolus Therapeutics and Neuralstem, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Autolus Therapeutics 0 0 3 0 3.00
Neuralstem 0 0 0 0 N/A

Autolus Therapeutics currently has a consensus price target of $25.00, indicating a potential upside of 145.10%. Given Autolus Therapeutics’ higher probable upside, research analysts clearly believe Autolus Therapeutics is more favorable than Neuralstem.

Insider & Institutional Ownership

26.6% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 38.3% of Neuralstem shares are owned by institutional investors. 5.4% of Neuralstem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Autolus Therapeutics beats Neuralstem on 7 of the 11 factors compared between the two stocks.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.

About Neuralstem

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.